Prostate Cancer and Prostatic Diseases - Table of Contents alert Volume 16 Issue 4

Advertisement Help contain the danger in mCRPC   XTANDI is a direct approach to treating metastatic castration-resistant prostate cancer (mCRPC) post-docetaxel.1-3 Help your patients live longer and achieve a better quality of life vs. placebo. With simple and convenient dosing, you can take hold of mCRPC in a brand new way.1-4 Click here for references and prescribing information. Date of preparation: September 2013. ENZ/13/0073/EU TABLE OF CONTENTS Volume 16, Issue 4 (December 2013) In this issue Original Articles Corrigenda Errata Also new AOP Advertisement   Disruption of prostate epithelial differentiation pathways and prostate cancer development (open access) In this review article, Sander B. Frank and Cindy K. Miranti review what is known about important differentiation pathways in the prostate (Myc, p38MAPK, Notch, PI3K/Pten) and how their misregulation in a transiently differentiating bipotent epithelial cell could lead to oncogenesis. Read more high-quality articles like this from Frontiers in Oncology  Sign up for e-alerts Recommend to your library Web feed Subscribe Original Articles Top Fish oil slows prostate cancer xenograft growth relative to other dietary fats and is associated with decreased mitochondrial and insulin pathway gene expression J C Lloyd, E M Masko, C Wu, M M Keenan, D M Pilla, W J Aronson, J-TA Chi and S J Freedland Prostate Cancer Prostatic Dis 2013 16: 285-291; advance online publication, July 23, 2013; 10.1038/pcan.2013.19 Abstract | Full Text Identification of novel DNA-methylated genes that correlate with human prostate cancer and high-grade prostatic intraepithelial neoplasia J M Devaney, S Wang, S Funda, J Long, D J Taghipour, R Tbaishat, P Furbert-Harris, M Ittmann and B Kwabi-Addo Prostate Cancer Prostatic Dis 2013 16: 292-300; advance online publication, July 30, 2013; 10.1038/pcan.2013.21 Abstract | Full Text SOX4 is associated with poor prognosis in prostate cancer and promotes epithelial–mesenchymal transition in vitro L Wang, J Zhang, X Yang, Y W Y Chang, M Qi, Z Zhou, J Zhang and B Han Prostate Cancer Prostatic Dis 2013 16: 301-307; advance online publication, August 6, 2013; 10.1038/pcan.2013.25 Abstract | Full Text Genetic variation in IL-16 miRNA target site and time to prostate cancer diagnosis in African-American men L Hughes, K Ruth, T R Rebbeck and V N Giri Prostate Cancer Prostatic Dis 2013 16: 308-314; advance online publication, September 24, 2013; 10.1038/pcan.2013.36 Abstract | Full Text Tanshinone IIA inhibits human prostate cancer cells growth by induction of endoplasmic reticulum stress in vitro and in vivo S C Chiu, S Y Huang, S P Chen, C C Su, T L Chiu and C Y Pang Prostate Cancer Prostatic Dis 2013 16: 315-322; advance online publication, September 17, 2013; 10.1038/pcan.2013.38 Abstract | Full Text Are post-docetaxel treatments effective in patients with castration-resistant prostate cancer and performance of 2? A meta-analysis of published trials R Iacovelli, A Altavilla, G Procopio, S Bracarda, M Santoni, S Cascinu and E Cortesi Prostate Cancer Prostatic Dis 2013 16: 323-327; advance online publication, July 30, 2013; 10.1038/pcan.2013.20 Abstract | Full Text Safety and efficacy of resistance exercise in prostate cancer patients with bone metastases P Cormie, R U Newton, N Spry, D Joseph, D R Taaffe and D A Galvão Prostate Cancer Prostatic Dis 2013 16: 328-335; advance online publication, August 6, 2013; 10.1038/pcan.2013.22 Abstract | Full Text Polymorphisms of the androgen transporting gene SLCO2B1 may influence the castration resistance of prostate cancer and the racial differences in response to androgen deprivation N Fujimoto, T Kubo, H Inatomi, H T T Bui, M Shiota, T Sho and T Matsumoto Prostate Cancer Prostatic Dis 2013 16: 336-340; advance online publication, July 30, 2013; 10.1038/pcan.2013.23 Abstract | Full Text Factors related to patient-perceived satisfaction after robot-assisted radical prostatectomy based on the expanded prostate cancer index composite survey J H Kim, Y-S Ha, S J Jeong, S Kim, W-J Kim, T L Jang and I Y Kim Prostate Cancer Prostatic Dis 2013 16: 341-345; advance online publication, August 6, 2013; 10.1038/pcan.2013.24 Abstract | Full Text Factors associated with improved biochemical response to neoadjuvant androgen deprivation therapy before definitive radiation therapy in prostate cancer patients J Z Cerne, S E McGuire, S R Grant, M F Munsell, A K Lee, R J Kudchadker, S L Choi, U Mahmood, K E Hoffman, T J Pugh, S J Frank and D A Kuban Prostate Cancer Prostatic Dis 2013 16: 346-351; advance online publication, August 13, 2013; 10.1038/pcan.2013.26 Abstract | Full Text Obese men have more advanced and more aggressive prostate cancer at time of surgery than non-obese men after adjusting for screening PSA level and age: results from two independent nested case–control studies OPEN A S Parker, D D Thiel, E Bergstralh, R E Carlson, L J Rangel, R W Joseph, N Diehl and R J Karnes Prostate Cancer Prostatic Dis 2013 16: 352-356; advance online publication, August 20, 2013; 10.1038/pcan.2013.27 Abstract | Full Text Pharmacodynamic study of disulfiram in men with non-metastatic recurrent prostate cancer M T Schweizer, J Lin, A Blackford, A Bardia, S King, A J Armstrong, M A Rudek, S Yegnasubramanian and M A Carducci Prostate Cancer Prostatic Dis 2013 16: 357-361; advance online publication, August 20, 2013; 10.1038/pcan.2013.28 Abstract | Full Text Role of combined use of ketoconazole and tamsulosin in management of acute urinary retention due to benign prostatic obstruction (a randomized controlled trial) M Elbendary, O M El-Gamal, M G Soliman, A Tawfik and M R Taha Prostate Cancer Prostatic Dis 2013 16: 362-366; advance online publication, September 10, 2013; 10.1038/pcan.2013.30 Abstract | Full Text Impact of statin use on biochemical recurrence in patients treated with radical prostatectomy M Rieken, L A Kluth, E Xylinas, C Seitz, H Fajkovic, P I Karakiewicz, Y Lotan, A Briganti, W Loidl, T Faison, J J Crivelli, D S Scherr, A Bachmann, A K Tewari, A Kautzky-Willer, K Pummer and S F Shariat Prostate Cancer Prostatic Dis 2013 16: 367-371; advance online publication, September 3, 2013; 10.1038/pcan.2013.31 Abstract | Full Text Prediction of prostate cancer to urethra distance by a pretreatment nomogram: urethral thermoprotection implication in cryoablation M M Padilha, J Stephen Jones, K Streator Smith, M Zhou, E Walker and C Magi-Galluzzi Prostate Cancer Prostatic Dis 2013 16: 372-375; advance online publication, September 3, 2013; 10.1038/pcan.2013.32 Abstract | Full Text High level of dioxin-TEQ in tissue is associated with Agent Orange exposure but not with biochemical recurrence after radical prostatectomy Q Li, L Lan, Z Klaassen, S R Shah, K A Moses and M K Terris Prostate Cancer Prostatic Dis 2013 16: 376-381; advance online publication, September 10, 2013; 10.1038/pcan.2013.33 Abstract | Full Text RTOG 0518: randomized phase III trial to evaluate zoledronic acid for prevention of osteoporosis and associated fractures in prostate cancer patients L A Kachnic, S L Pugh, P Tai, M Smith, E Gore, A B Shah, A-G Martin, H E Kim, A Nabid and C A F Lawton Prostate Cancer Prostatic Dis 2013 16: 382-386; advance online publication, October 1, 2013; 10.1038/pcan.2013.35 Abstract | Full Text Emerging association between androgen deprivation therapy and male meningioma: significant expression of luteinizing hormone-releasing hormone receptor in male meningioma Q Li, H Coulson, Z Klaassen, S Sharma, P Ramalingam, K A Moses and M K Terris Prostate Cancer Prostatic Dis 2013 16: 387-390; advance online publication, October 8, 2013; 10.1038/pcan.2013.45 Abstract | Full Text Metformin does not affect risk of biochemical recurrence following radical prostatectomy: results from the SEARCH database E H Allott, M R Abern, L Gerber, C J Keto, W J Aronson, M K Terris, C J Kane, C L Amling, M R Cooperberg, P G Moorman and S J Freedland Prostate Cancer Prostatic Dis 2013 16: 391-397; advance online publication, October 8, 2013; 10.1038/pcan.2013.48 Abstract | Full Text Corrigenda Top Accurate prediction of repeat prostate biopsy outcomes by a mitochondrial DNA deletion assay K Robinson, J Creed, B Reguly, C Powell, R Wittock, D Klein, A Maggrah, L Klotz, R L Parr and G D Dakubo Prostate Cancer Prostatic Dis 2013 16: 398; 10.1038/pcan.2013.42 Full Text Oxidative stress in prostate cancer: changing research concepts towards a novel paradigm for prevention and therapeutics A Paschos, R Pandya, W C M Duivenvoorden and J H Pinthus Prostate Cancer Prostatic Dis 2013 16: 398; 10.1038/pcan.2013.39 Full Text Fish oil slows prostate cancer xenograft growth relative to other dietary fats and is associated with decreased mitochondrial and insulin pathway gene expression J C Lloyd, E M Masko, C Wu, M M Keenan, D M Pilla, W J Aronson, J-TA Chi and S J Freedland Prostate Cancer Prostatic Dis 2013 16: 398; 10.1038/pcan.2013.29 Full Text Errata Top Transcriptional and post-transcriptional regulation of Sprouty1, a receptor tyrosine kinase inhibitor in prostate cancer M Darimipourain, S Wang, M Ittmann and B Kwabi-Addo Prostate Cancer Prostatic Dis 2013 16: 399; 10.1038/pcan.2013.47 Full Text Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to Prostate Cancer and Prostatic Diseases. In order to do so, please purchase a subscription. You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2013 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.